Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Candonilimab + ATRA for Prevention of Oral Cancer Recurrence
NCT06728631Phase 2Active, not recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Jun 2020
- Primary completion
- Dec 2023
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in oral cavity cancer (OCC), Oral potentially malignant disorders (OPMD), sponsored by Shanghai Ninth People's Hospital. Started Jun 2020; status: active, not recruiting.
02
Drugs
cadonilimab
03
Conditions
oral cavity cancer (OCC)Oral potentially malignant disorders (OPMD)
Beyond the preview
Go deeper on NCT06728631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06728631.